Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities
-- Deal Leverages Complementary Strengths for Both Research Triangle
Park Employers --
-- Reinforces Local Presence through Increased Capacity Utilization --
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Biogen
Idec (NASDAQ: BIIB) and Eisai
Inc. today announced a strategic alliance that will bolster the
manufacturing capabilities of both companies’ Research Triangle Park
(RTP)-based facilities. Under the terms of the agreement, Biogen Idec
will lease a portion of the Eisai facility to manufacture oral solid
dose products for both companies. Eisai will provide Biogen Idec with
vial-filling services for biologic therapies and packaging services for
oral solid dose products. The 10-year lease agreement gives Biogen Idec
the option to purchase the Eisai oral solid dose facility.
“We view our supply chain as a lifeline to patients, designed to deliver
quality therapies wherever and whenever they are needed,” said John G.
Cox, executive vice president of Pharmaceutical Operations and
Technology, for Biogen Idec. “This innovative capacity-sharing
relationship with Eisai fits strategically in our global drug supply
network, particularly as we advance our oral therapeutics.”
Approximately 50 Eisai personnel are expected to become Biogen Idec
employees in early 2013, building on the company’s RTP workforce which
exceeded 1,000 in 2012. Eisai currently employs approximately 225
full-time employees at its RTP site.
"We look forward to collaborating with Biogen Idec to continue the proud
history of drug manufacturing excellence here at our RTP site," said Lou
Arp, general manager of the Eisai RTP site and president of Global
Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both
companies to focus on respective areas of expertise while continuing to
deliver high-quality and innovative products to patients. Moreover,
employees will benefit by working in a highly collaborative environment
that offers opportunities to further cultivate their careers.”
Biogen Idec and Eisai have both operated manufacturing facilities in RTP
since the mid-1990s. “This alliance underscores the Triangle region’s
reputation as a globally competitive location for life sciences,” said
Bob Geolas, president and CEO of the Research Triangle Foundation. “In
addition, it’s an illustration of the type of collaboration we encourage
and foresee becoming more commonplace as the Park moves forward with its
new Master Plan.”
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers,
develops and delivers to patients worldwide innovative therapies for the
treatment of neurodegenerative diseases, hemophilia and autoimmune
disorders. Founded in 1978, Biogen Idec is the world’s oldest
independent biotechnology company. Patients worldwide benefit from its
leading multiple sclerosis therapies, and the company generates more
than $5 billion in annual revenues. For product labeling, press releases
and additional information about the company, please visit www.biogenidec.com.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product
in the United States in 1997. Since that time, Eisai Inc. has rapidly
grown to become a fully integrated pharmaceutical business. Eisai's key
areas of commercial focus are neurology and oncology. The company serves
as the U.S. pharmaceutical operation of Eisai Co., Ltd., a
research-based human health care (hhc) company that discovers, develops
and markets products throughout the world. Eisai has a global product
creation organization that includes U.S.-based R&D facilities in
Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as
manufacturing facilities in Maryland and North Carolina. The company's
areas of R&D focus include neuroscience; oncology; vascular,
inflammatory and immunological reaction; and antibody-based programs.
For more information about Eisai, please visit www.eisai.com/US.
Biogen Idec Media Contact: Mike McBrierty, 919-993-6368 Senior
Manager, Public Affairs or Biogen Idec Investor Contact: Benjamin
Strain, 781-464-2442 Senior Manager, Investor Relations or Eisai
Inc. Media Contact: Lynn Kenney, 201-746-2294 Senior
Director, Corporate Communications or Eisai Inc. Investor
Contact: Alex Scott, 201-746-2177 Vice President,
Commercial Development
Source: Biogen Idec
SHARE THIS:
SHORT URL: http://bdvt.co/BJy
MEDIA
No media uploaded.
INFO
About
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin
Press Release $BIIB Biogen Idec Inc.
-- Deal Leverages Complementary Strengths for Both Research Triangle Park Employers --
-- Reinforces Local Presence through Increased Capacity Utilization --
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB) and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both companies’ Research Triangle Park (RTP)-based facilities. Under the terms of the agreement, Biogen Idec will lease a portion of the Eisai facility to manufacture oral solid dose products for both companies. Eisai will provide Biogen Idec with vial-filling services for biologic therapies and packaging services for oral solid dose products. The 10-year lease agreement gives Biogen Idec the option to purchase the Eisai oral solid dose facility.
“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”
Approximately 50 Eisai personnel are expected to become Biogen Idec employees in early 2013, building on the company’s RTP workforce which exceeded 1,000 in 2012. Eisai currently employs approximately 225 full-time employees at its RTP site.
"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”
Biogen Idec and Eisai have both operated manufacturing facilities in RTP since the mid-1990s. “This alliance underscores the Triangle region’s reputation as a globally competitive location for life sciences,” said Bob Geolas, president and CEO of the Research Triangle Foundation. “In addition, it’s an illustration of the type of collaboration we encourage and foresee becoming more commonplace as the Park moves forward with its new Master Plan.”
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.
Biogen Idec Media Contact:
Mike McBrierty, 919-993-6368
Senior Manager, Public Affairs
or
Biogen Idec Investor Contact:
Benjamin Strain, 781-464-2442
Senior Manager, Investor Relations
or
Eisai Inc. Media Contact:
Lynn Kenney, 201-746-2294
Senior Director, Corporate Communications
or
Eisai Inc. Investor Contact:
Alex Scott, 201-746-2177
Vice President, Commercial Development
Source: Biogen Idec